KalshiComprobar disponibilidadKYC requeridoDatos de resolución verificadosBien calibradoPunto medio del libro seleccionado
Before Jan 1, 2029 · —
Cargando el libro seleccionado…
—
Precio guardado
Before Jan 1, 2029 89.5%Líder entre 5 opciones
Before Jan 1, 2029 89.5%Calidad del mercado
59 / 100
Calidad mediaVolumen 24h
46,9 €
Interés abierto
24,4 mil US$
Interés abierto medioCompra / Venta
— / —
Before Jan 1, 2029Spread
—
Datos de mercado
Actualizado hace 10 minutos
14 may 26, 2:00 UTC1 ene 27, 15:00 UTC
El gráfico y los cambios muestran probabilidades históricas guardadas, no el libro seleccionado en directo.
Tendencias
Fila seleccionada: punto medio del libro. Otras filas: referencias guardadas, posiblemente normalizadas; los cambios de 24h usan el historial guardado.
Condiciones de la plataforma
Fuente: Kalshi
Estas condiciones son informativas; las operaciones simuladas de CoinRithm siguen sus propias reglas.
- Cierre anticipado:
- Sí
- Plazo de liquidación:
- 30m (informativo)
Profundidad de mercado · Before Jan 1, 2029
Cargando el libro seleccionado…
—
Mercados Relacionados
Preguntas relacionadas para dar contexto, no una comparación de contratos equivalentes.
When will the FDA approve Intellia Therapeutics' lonvo-z?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
KalshiWill the FDA approve a cure for Type 1 diabetes before 2033?
KalshiWill FDA approve any mRNA vaccine against melanoma before 2028?
Manifold MarketsWill FDA approve any mRNA vaccine against any type of herpes simplex infection before 2028?
Manifold MarketsReglas
If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2029, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
Liquida mediante:Food and Drug Administration
Reglas de cada resultado
- Before Jan 1, 2029
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2029, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jul 1, 2028
- If the FDA approves retatrutide (LY3437943) for marketing before Jul 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2028
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jul 1, 2027
- If the FDA approves retatrutide (LY3437943) for marketing before Jul 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2027
- If the FDA approves retatrutide (LY3437943) for marketing before Jan 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
